News Headlines

  1. Abolis Biotechnologies And EUROAPI Enter Into Partnership To Accelerate Pharmaceutical Innovation And Restore European Sovereignty 10/23/2025

    Abolis Biotechnologies, a company specializing in industrial solutions using microorganisms, today announced that it has entered into a strategic partnership with EUROAPI, one of the world’s leading producers of active pharmaceutical ingredients, for the development of microbial strains for the synthesis of key intermediates and 20 active ingredients, particularly from the corticosteroid family.

  2. AGC Biologics Partners With Rarity PBC To Advance Life-Saving Gene Therapy For 'Bubble Baby Disease' 10/23/2025

    AGC Biologics, your friendly CDMO expert, today announced an agreement with Rarity PBC to provide comprehensive development and Good Manufacturing Practice (GMP) manufacturing for Rarity's gene therapy, RDP-101, for Adenosine Deaminase Severe Combined Immunodeficiency Disorder.

  3. SK pharmteco Boosts Domestic Peptide Scale-Up With Investment In California Facility 10/23/2025

    SK pharmteco, a global contract development and manufacturing organization (CDMO), announced today a $6.1M investment in its Rancho Cordova facility to expand and equip a new lab and CGMP-Kilo-scale facility for Solid-Phase Peptide Synthesis (SPPS) and purification.

  4. Aenova Expands Sterile Fill & Finish Manufacturing Capacity At Its Latina Site 10/23/2025

    Aenova, a leading global contract development and manufacturing organization (CDMO), announces a major investment in its sterile manufacturing capabilities with the installation of another fill & finish (F&F) line at its Latina site.

  5. Upperton Expands High Precision Filling Capability At Nottingham Facility 10/22/2025

    The system has been installed at Upperton’s state-of-the-art 60,000-square-foot GMP facility. The site supports formulation development and clinical manufacturing across a broad range of dosage forms, including oral solids, nasal, pulmonary and parenteral.

  6. Cambrex Unveils $120 Million Investment To Expand API Manufacturing And Strengthen U.S. Drug Supply Resilience 10/22/2025

    Cambrex, a leading global CDMO, is addressing increased demand for API development and manufacturing and accelerating the company’s leadership role in the fast-growing peptide therapeutics market.

  7. Invenra Inc. And Xcellon Biologics Announce Collaboration To Advance Bispecific And Trispecific Antibody-Drug Conjugate (ADC) Development 10/22/2025

    Invenra Inc., a U.S.-based biotechnology company pioneering multispecific antibody platform technologies, and Xcellon Biologics, a wholly owned subsidiary of Linden Lake Labs and a U.S.-based contract development and manufacturing organization (CDMO) specializing in antibody–drug conjugates (ADCs) and complex biologics, today announced a strategic collaboration to advance the development of multispecific ADCs.

  8. Syngene International Announces Plans To Add Bioconjugation Suite For End-To-End Antibody-Drug Conjugates Development 10/22/2025

    Syngene International, a global contract research, development and manufacturing organization (CRDMO), is adding a GMP bioconjugation suite at its commercial biologics facility [Unit 3] in Bengaluru.

  9. Serán BioScience Expands Commercial Serán BioScience Expands Commercial Manufacturing With New 100,000 sq. ft. Campus In Bend, Oregon 10/22/2025

    Serán BioScience, LLC, a leading science-driven drug development partner, today announced the completion of two of the three new buildings and commencement of construction of the third facility for of its new 100,000 sq. ft. commercial manufacturing campus in Bend, Oregon.

  10. Ajinomoto Bio-Pharma Services And Gene Tools Announce Collaboration To Expand Access To PMO Therapeutics 10/22/2025

    Ajinomoto Bio-Pharma Services (“Aji Bio-Pharma”), a leading provider of biopharmaceutical contract development and manufacturing services, and Gene Tools, LLC (Gene Tools) today announced a formal collaboration to broaden access to phosphorodiamidate morpholino oligomers (PMOs), a unique class of oligonucleotide therapeutics with significant potential for treating a broad range of genetic diseases, such as Duchenne muscular dystrophy (DMD).